Amacım ilkelerimizi, karşılaştığımız sorunları, yayımcılıkla ilgili görüşlerimizi dile getirmek, ... more Amacım ilkelerimizi, karşılaştığımız sorunları, yayımcılıkla ilgili görüşlerimizi dile getirmek, dergimizi tanıtmaktır. 2000 yılında ) numarasıyla yayım hayatına başlamanın ve yayınımızı bugüne kadar sürdürmenin mutluluğunu yaşıyoruz. Dergimiz, periodik, 4ayda bir çıkan süreli, ...
Organ-on-a-chip technology has been used in testing small-molecule drugs for screening potential ... more Organ-on-a-chip technology has been used in testing small-molecule drugs for screening potential therapeutics and regulatory protocols. The technology is expected to boost the development of novel therapies and accelerate the discovery of drug combinations in the coming years. This has led to the development of multi-organ-on-a-chip (MOC) for recapitulating various organs involved in the drug–body interactions. In this review, we discuss the current MOCs used in screening small-molecule drugs and then focus on the dynamic process of drug absorption, distribution, metabolism, and excretion. We also address appropriate materials used for MOCs at low cost and scale-up capacity suitable for high-performance analysis of drugs and commercial high-throughput screening platforms.
The purpose of this study is to evaluate anti-inflammatory and chondro-protective effects of 1,25... more The purpose of this study is to evaluate anti-inflammatory and chondro-protective effects of 1,25(OH)2D3 in human chondrocytes and SW1353 cells via investigating expressions of MMPs, TIMPs, VDR, and intracellular signalling pathway mediators such as TLR-2 and -4. The HC and SW1353 cells were treated with 1,25(OH)2D3 at 10, 100, and 1000 nM concentrations in the absence/presence of TNF-α (20 ng/mL) for 48 h. The mRNA expressions of MMP-1, -2, -3, -9, and -13, TIMP-1 and -2, VDR, TLR-2 and -4 in HC and SW1353 cells were detected by qPCR after treatments. The cytotoxicity and cell proliferation analyses were assessed by LDH and WST-1 assay, respectively. Protein levels of MMPs, TIMPs, and VDR were analysed by immunocytochemistry and ELISA methods. TNF-α markedly increased cytotoxicity for 24, 48, 72 h (p < 0.05) and vitamin D treatment was shown to diminish the cytotoxic effect of TNF-α. Cell proliferations increased by Vitamin D in a dose-dependent manner. mRNA expressions of MMP-1, -2, -3, -9, and -13, TLR-2 and -4 genes decreased with 1,25(OH)2D3 treatment (p < 0.05). VDR, TIMP-1 and -2 levels elevated after TNF-α exposure compared with the control group in HC cells (p < 0.05). Protein expression levels were determined using Western blotting, ELISA and immunocytochemistry. 1,25(OH)2D3 via binding to VDR, reversed the effects of TNF-α by inhibiting TLR-2 and 4. Decreased levels of VDR, TIMP-1 and -2 after TNF-α treatment were elevated by 1,25(OH)2D3 proportional with increasing 1,25(OH)2D3 doses. 1,25(OH)2D3 and TNF-α co-treatment decreased MMP-1, -2, -3, -9, and -13 levels were after TNF-α exposure.
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting sacroiliac ... more Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting sacroiliac joints and spine as well as peripheral joints and entheses. Tumour necrosis factor inhibitors (TNFi) are widely used in patients with persistently high disease activity despite non-steroidal anti-inflammatory drugs. Some patients fail to respond or loose responsiveness during therapy with TNFi. The development of anti-drug antibodies (ADA) might play a role in non-response or some adverse events. However it has never been evaluated for 2-years period.Therefore, the aim of the present study was to evaluate the development of ADA against TNFi longitudinally during 2-years period in axSpA patients and factors associated with it.In total 180 axSpA patients according to ASAS classification criteria with a new TNFi prescription in the last two weeks period were included in this observational study. Clinical data and serum samples were collected at baseline and at every 12 weeks. Serum drug lev...
Comparison of Neuropeptide Innervation in Allergic and Nonallergic Rhinitis Background: Rhinitis ... more Comparison of Neuropeptide Innervation in Allergic and Nonallergic Rhinitis Background: Rhinitis can be induced by different mechanisms and involves several etiological agents. It is important to differentiate between allergic rhinitis (AR) and nonallergic rhinitis (NAR), as management differs for each. Objective: We aimed to study the several biomarkers of allergic rhinitis and nonallergic rhinitis to investigate their potential as outcome measures in clinical intervention trials. Materials and Methods: All study groups were compared in terms of mucociliary clearance time, air flow level, and various neuropeptids in nasal fluid. All groups were evaluated for asthma by a respiratory medicine specialist performing pulmonary function testing.
Amacım ilkelerimizi, karşılaştığımız sorunları, yayımcılıkla ilgili görüşlerimizi dile getirmek, ... more Amacım ilkelerimizi, karşılaştığımız sorunları, yayımcılıkla ilgili görüşlerimizi dile getirmek, dergimizi tanıtmaktır. 2000 yılında ) numarasıyla yayım hayatına başlamanın ve yayınımızı bugüne kadar sürdürmenin mutluluğunu yaşıyoruz. Dergimiz, periodik, 4ayda bir çıkan süreli, ...
Organ-on-a-chip technology has been used in testing small-molecule drugs for screening potential ... more Organ-on-a-chip technology has been used in testing small-molecule drugs for screening potential therapeutics and regulatory protocols. The technology is expected to boost the development of novel therapies and accelerate the discovery of drug combinations in the coming years. This has led to the development of multi-organ-on-a-chip (MOC) for recapitulating various organs involved in the drug–body interactions. In this review, we discuss the current MOCs used in screening small-molecule drugs and then focus on the dynamic process of drug absorption, distribution, metabolism, and excretion. We also address appropriate materials used for MOCs at low cost and scale-up capacity suitable for high-performance analysis of drugs and commercial high-throughput screening platforms.
The purpose of this study is to evaluate anti-inflammatory and chondro-protective effects of 1,25... more The purpose of this study is to evaluate anti-inflammatory and chondro-protective effects of 1,25(OH)2D3 in human chondrocytes and SW1353 cells via investigating expressions of MMPs, TIMPs, VDR, and intracellular signalling pathway mediators such as TLR-2 and -4. The HC and SW1353 cells were treated with 1,25(OH)2D3 at 10, 100, and 1000 nM concentrations in the absence/presence of TNF-α (20 ng/mL) for 48 h. The mRNA expressions of MMP-1, -2, -3, -9, and -13, TIMP-1 and -2, VDR, TLR-2 and -4 in HC and SW1353 cells were detected by qPCR after treatments. The cytotoxicity and cell proliferation analyses were assessed by LDH and WST-1 assay, respectively. Protein levels of MMPs, TIMPs, and VDR were analysed by immunocytochemistry and ELISA methods. TNF-α markedly increased cytotoxicity for 24, 48, 72 h (p < 0.05) and vitamin D treatment was shown to diminish the cytotoxic effect of TNF-α. Cell proliferations increased by Vitamin D in a dose-dependent manner. mRNA expressions of MMP-1, -2, -3, -9, and -13, TLR-2 and -4 genes decreased with 1,25(OH)2D3 treatment (p < 0.05). VDR, TIMP-1 and -2 levels elevated after TNF-α exposure compared with the control group in HC cells (p < 0.05). Protein expression levels were determined using Western blotting, ELISA and immunocytochemistry. 1,25(OH)2D3 via binding to VDR, reversed the effects of TNF-α by inhibiting TLR-2 and 4. Decreased levels of VDR, TIMP-1 and -2 after TNF-α treatment were elevated by 1,25(OH)2D3 proportional with increasing 1,25(OH)2D3 doses. 1,25(OH)2D3 and TNF-α co-treatment decreased MMP-1, -2, -3, -9, and -13 levels were after TNF-α exposure.
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting sacroiliac ... more Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting sacroiliac joints and spine as well as peripheral joints and entheses. Tumour necrosis factor inhibitors (TNFi) are widely used in patients with persistently high disease activity despite non-steroidal anti-inflammatory drugs. Some patients fail to respond or loose responsiveness during therapy with TNFi. The development of anti-drug antibodies (ADA) might play a role in non-response or some adverse events. However it has never been evaluated for 2-years period.Therefore, the aim of the present study was to evaluate the development of ADA against TNFi longitudinally during 2-years period in axSpA patients and factors associated with it.In total 180 axSpA patients according to ASAS classification criteria with a new TNFi prescription in the last two weeks period were included in this observational study. Clinical data and serum samples were collected at baseline and at every 12 weeks. Serum drug lev...
Comparison of Neuropeptide Innervation in Allergic and Nonallergic Rhinitis Background: Rhinitis ... more Comparison of Neuropeptide Innervation in Allergic and Nonallergic Rhinitis Background: Rhinitis can be induced by different mechanisms and involves several etiological agents. It is important to differentiate between allergic rhinitis (AR) and nonallergic rhinitis (NAR), as management differs for each. Objective: We aimed to study the several biomarkers of allergic rhinitis and nonallergic rhinitis to investigate their potential as outcome measures in clinical intervention trials. Materials and Methods: All study groups were compared in terms of mucociliary clearance time, air flow level, and various neuropeptids in nasal fluid. All groups were evaluated for asthma by a respiratory medicine specialist performing pulmonary function testing.
Uploads
Papers by Didem Kozaci